Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Susan Lee"


3 mentions found


The Battle for The Streets of New York
  + stars: | 2024-05-13 | by ( Dodai Stewart | ) www.nytimes.com   time to read: +11 min
New York City streets and sidewalks have always been crowded, but it’s never been like this. But lately, New York City streets are teetering between lively and unlivable. Karsten Moran for The New York Times“I think this could be the catalyst for a streets renaissance in New York,” Janette Sadik-Khan, New York City’s former transportation commissioner, said in a recent interview. New York City’s population reached 8.8 million in 2020, and the New York region is now home to nearly 19 million people. Use this form to tell us what you think about the state of New York City’s streets.
Persons: it’s, Karsten Moran, ” Janette Sadik, , , Susan Lee, William Notman, Jon Orcutt, you’re, , Henry Hale Bliss, Bliss, James Nevius, George Rinhart, Damon Winter, Sadik, Yorkers who’ve, Ms, Khan Organizations: New, Lexington, Verizon, FedEx, The New York Times, Broadway, Getty, Yorkers, Brooklyn baseball, Midtown, Bike New, city’s Department of Transportation, Park West, Times, New York Times, Cycling Locations: New York City, New York, Manhattan, , New York, York, York’s, Midtown —, Bike New York, United States, Holland, Jackson, Queens, Bogotá, Stockholm, London, Paris, Europe,
WASHINGTON, April 10 (Reuters) - A federal judge's decision last week to suspend the U.S. Food and Drug Administration's (FDA) approval of abortion pill mifepristone could severely weaken the agency if allowed to stand, health policy and legal experts said. The FDA approved mifepristone, part of a two-drug regimen that accounts for more than half of U.S. abortions, over 20 years ago. Banning its sale calls into question the FDA's power to regulate all drugs nationwide, the experts said. The challenge was brought by a coalition of anti-abortion groups and doctors seeking withdrawal of the FDA's mifepristone approval before Kacsmaryk, who is himself a conservative former Christian activist. Plaintiffs are arguing that the FDA in its 2000 approval did not adequately consider the drug's safety when used by girls under age 18 to terminate a pregnancy.
Any impact on the FDA will depend on details of the judge's ruling in the case known as Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration. The challenge was brought by a coalition of anti-abortion groups and doctors seeking withdrawal of the FDA's mifepristone approval before U.S. District Judge Matthew Kacsmaryk of the Northern District of Texas, a conservative former Christian activist. The court could order mifepristone pulled from the market while it considers a final ruling. It would call into question the entire drug approval process, said Laurie Sobel, associate director for Women's Health Policy at the Kaiser Family Foundation. 'SO MUCH UNCERTAINTY'The possibility of its approvals being overruled would likely see the FDA become more cautious, Lee said.
Total: 3